-
EP3781168
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3781168
| EP3781168 - PAK4 INHIBITORS AND METHODS OF USE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 22.01.2021 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 25.10.2019 | Most recent event Tooltip | 29.04.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US | [2021/08] | Inventor(s) | 01 /
RIBAS, Antoni c/o The Regents of the University of California 1111 Franklin Street 12th Floor Oakland, CA 94607 / US | 02 /
RODRIGUEZ, Gabriel, Abril c/o The Regents of the University of California 1111 Franklin Street 12th Floor Oakland, CA 94607 / US | 03 /
GRASSO, Catherine c/o The Regents of the University of California 1111 Franklin Street 12th Floor Oakland, CA 94607 / US | 04 /
TORREJON, Davis, Y. c/o The Regents of the University of California 1111 Franklin Street 12th Floor Oakland, CA 94607 / US | [2021/08] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2021/08] | J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 19788159.2 | 16.04.2019 | [2021/08] | WO2019US27716 | Priority number, date | US201862658136P | 16.04.2018 Original published format: US 201862658136 P | US201862743062P | 09.10.2018 Original published format: US 201862743062 P | [2021/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2019204332 | Date: | 24.10.2019 | Language: | EN | [2019/43] | Type: | A2 Application without search report | No.: | EP3781168 | Date: | 24.02.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.10.2019 takes the place of the publication of the European patent application. | [2021/08] | Search report(s) | International search report - published on: | US | 28.11.2019 | (Supplementary) European search report - dispatched on: | EP | 07.09.2022 | Classification | IPC: | A61K31/7105, A61K31/53, A61K31/506, A61K31/519, A61K31/5377, A61K39/395, C12N9/12, C12N9/99, A61P35/02, A61P35/04, A61K45/06 | [2022/27] | CPC: |
C12N15/1137 (EP);
A61K31/7105 (EP,US);
A61K31/4545 (US);
A61K39/3955 (EP);
A61K45/06 (EP,US);
A61P35/00 (US);
C07K16/2818 (EP,US);
C07K16/2827 (US);
A61K2039/505 (EP);
A61K2039/507 (US);
C07H9/06 (US);
C12N2310/20 (EP);
| C-Set: |
A61K31/7105, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (EP) |
| Former IPC [2021/08] | A61K31/53, A61K31/506, A61K31/519, A61K31/5377, A61K39/395, C12N9/12, C12N9/99, A61P35/02, A61P35/04 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/08] | Title | German: | PAK4-HEMMER UND VERFAHREN ZUR VERWENDUNG | [2021/08] | English: | PAK4 INHIBITORS AND METHODS OF USE | [2021/08] | French: | INHIBITEURS DE PAK4 ET PROCÉDÉS D'UTILISATION | [2021/08] | Entry into regional phase | 30.10.2020 | National basic fee paid | 30.10.2020 | Search fee paid | 30.10.2020 | Designation fee(s) paid | 30.10.2020 | Examination fee paid | Examination procedure | 30.10.2020 | Examination requested [2021/08] | 29.03.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.04.2021 | Renewal fee patent year 03 | 27.04.2022 | Renewal fee patent year 04 | 27.04.2023 | Renewal fee patent year 05 | 29.04.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2007023382 (PFIZER [US], et al); | [XI]US2012264751 (ZHANG JUNHU [US], et al); | International search | [A]WO2007023382 (PFIZER [US], et al); | [XY]WO2017197036 (C4 THERAPEUTICS INC [US]); | [XP]WO2019033041 (UNIV TEXAS [US]); |